Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.

(Reuters) -Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...

(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

The European Medicines Agency has granted restricted EU authorization to Eli Lilly’s Alzheimer’s drug Kisunla, reversing an ...

Kisunla comes as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). Your doctor or another healthcare professional will give you the infusions.

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...